1. 0 5 10 15 20 25 30 35 40 BluntPenetrating Placebo rFVIIa Patients (%) n=20 n=8 n=9 n=4 P=0.03 P=0.068 Adapted from Rizoli S. Canadian Anesthesiologists’ Society Annual Meeting 2007. Need for Massive Transfusion (>20 units RBC): A Secondary Analysis

2. Comparison Odds ratio CI P value Entire patient cohort (unadjusted) All rFVIIa vs. no rFVIIa 2.41 1.56-3.67 <0.0001 Late rFVIIa vs. no rFVIIa 4.88 2.64-8.98 <0.0001 Early rFVIIa vs. no rFVIIa 1.39 0.79-2.43 0.30 Entire patient cohort (adjusted) All rFVIIa vs. no rFVIIa 1.04 0.60-1.81 0.90 Late rFVIIa vs. no rFVIIa 1.12 0.51-2.49 0.90 Early rFVIIa vs. no rFVIIa 0.99 0.51-1.91 0.80 Only rFVIIa-treated patients (adjusted) Early rFVIIa vs. no rFVIIa 0.41 0.18-0.92 0.30 Adapted from Karkouti et al. Can an J Anaesth 2006;53(8):802-9. Risk of Adverse Events in 114 rFVIIa-treated Patients

3. Placebo (n=63) rFVIIa (n=49) Reduction P-value RBC (unit) 6.35 2.95 3.40 <0.01 FFP (mL) 1,320 660 <0.01 Platelets (mL) 263 100 163 0.04 Adapted from Rizoli S. Canadian Anesthesiologists Society 2007. Blood Transfusion Requirement in Coagulopathic Patients